Amniotic Suspension Allograft for Knee Osteoarthritis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called Amniotic Suspension Allograft (ASA) to determine its effectiveness and safety for people with knee osteoarthritis (OA), a condition causing joint pain and stiffness. Participants will receive either the ASA treatment or a placebo (a harmless substance resembling the treatment but without active ingredients) to compare outcomes. It suits individuals diagnosed with knee OA who have tried at least two other treatments without success in the past year and experience significant knee pain affecting daily life. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to a potentially groundbreaking treatment for knee OA.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop taking your current medications, but you cannot use pain medication less than 5 days before the baseline visit or regularly use anticoagulants. It's best to discuss your specific medications with the trial team.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that Amniotic Suspension Allograft (ASA) is generally safe for people. In a study comparing ASA to a saltwater solution for treating knee osteoarthritis, ASA led to better results without major safety issues. Specifically, 63.2% of participants reported relief after 12 months. Importantly, this study found no serious side effects linked to ASA, suggesting that ASA is a safe option for managing knee osteoarthritis symptoms.12345
Why do researchers think this study treatment might be promising for knee osteoarthritis?
Unlike standard treatments for knee osteoarthritis, which often include NSAIDs, corticosteroid injections, or hyaluronic acid, the Amniotic Suspension Allograft (ASA) is derived from amniotic fluid. This gives it unique regenerative properties that might help repair and cushion knee cartilage. Researchers are excited because ASA could potentially offer longer-lasting relief and promote healing rather than just masking pain. Additionally, its single injection approach could simplify treatment compared to multiple doses required by other therapies.
What evidence suggests that Amniotic Suspension Allograft might be an effective treatment for knee osteoarthritis?
Research has shown that Amniotic Suspension Allograft (ASA), which participants in this trial may receive, can help people with knee osteoarthritis by reducing pain and improving joint function. In one study, patients who received ASA reported less pain and increased activity for up to 12 months after treatment. Another review found ASA effective in reducing pain and improving movement in people with knee osteoarthritis. Animal studies also showed positive results, suggesting ASA might help repair joint damage. Overall, these findings support ASA's potential as an effective treatment for knee osteoarthritis symptoms.23467
Are You a Good Fit for This Trial?
Adults over 18 with a BMI under 40 and moderate to severe knee osteoarthritis, who haven't responded well to other treatments for at least six months. Participants must not be on immunosuppressives or have recent knee injuries/surgeries, infections, or conditions that could affect safety or data quality. They should use birth control if applicable.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single intra-articular injection of ASA or placebo
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Amniotic Suspension Allograft
- Placebo
Amniotic Suspension Allograft is already approved in United States for the following indications:
- Wound healing
- Osteoarthritis symptoms management
Find a Clinic Near You
Who Is Running the Clinical Trial?
Organogenesis
Lead Sponsor